ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel

ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel

<p>Abstract</p> <p>Background</p> <p>One of the major challenges in currently chemotherapeutic theme is lacking effective biomarkers for drug response and sensitivity. Our current study focus on two promising biomarkers, ERCC1 (excision repair cross-complementing group...

Full description

Bibliographic Details
Main Authors:	Wang Tingting, Yu Lixia, Zhao Yang, Yin Haitao, Qian Xiaoping, Wei Jia, Wang Lifeng, Liu Baorui
Format:	Article
Language:	English
Published:	BMC 2008-04-01
Series:	BMC Cancer
Online Access:	http://www.biomedcentral.com/1471-2407/8/97

Similar Items

BRCA1 mRNA expression as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma treated with cisplatin- or docetaxel-based chemotherapy/chemoradiotherapy.
by: Yong Gao, et al.
Published: (2013-01-01)

Cell-free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions
by: Ding Yitao, et al.
Published: (2010-10-01)

The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients
by: Hadeel Obiedat, et al.
Published: (2018-07-01)

BRCA1 Expression is an Important Biomarker for Chemosensitivity: Suppression of BRCA1 Increases the Apoptosis via Up-regulation of p53 and p21 during Cisplatin Treatment in Ovarian Cancer Cells
by: Akiko Horiuchi, et al.
Published: (2006-01-01)

BRCA1 Expression is an Important Biomarker for Chemosensitivity: Suppression of BRCA1 Increases the Apoptosis via Up-regulation of p53 and p21 During Cisplatin Treatment in Ovarian Cancer Cells
by: Ikuo Konishi, et al.
Published: (2006-01-01)

Meta-Analysis of ERCC1 Protein Expression and Platinum Chemosensitivity in Non-Small-Cell Lung Cancer
by: Guoping Li, et al.
Published: (2020-01-01)

The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
by: Song WH, et al.
Published: (2016-06-01)

ERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinoma
by: Bai Zhou-lan, et al.
Published: (2012-12-01)

Effect of docetaxel + oxaliplatin + S-1 and docetaxel + cisplatin + fluorouracil on treatment of advanced gastric cancer
by: Wei Li, et al.
Published: (2016-09-01)

VEGFR3 Inhibition Chemosensitizes Ovarian Cancer Stemlike Cells through Down-Regulation of BRCA1 and BRCA2
by: Jaeyoung Lim, et al.
Published: (2014-04-01)

ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis
by: Yuqiang Zhang, et al.
Published: (2021-06-01)

Cisplatin in breast cancer treatment in BRCA1 carriers
by: Gronwald Jacek, et al.
Published: (2012-12-01)

Synergistic anti-proliferative effects of gambogic acid with docetaxel in gastrointestinal cancer cell lines
by: Zou Zhengyun, et al.
Published: (2012-04-01)

ERCC1 and ERCC2 variants predict survival in gastric cancer patients.
by: Yangkai Li, et al.
Published: (2013-01-01)

Increased mRNA expression levels of <it>ERCC1</it>, <it>OGG1 </it>and <it>RAI </it>in colorectal adenomas and carcinomas
by: Hansteen Inger-Lise, et al.
Published: (2006-08-01)

Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy
by: Leng Xue-Feng, et al.
Published: (2012-03-01)

Downregulation of TGF-β1 suppressed proliferation and increased chemosensitivity of ovarian cancer cells by promoting BRCA1/Smad3 signaling
by: Yanqiu Wang, et al.
Published: (2018-12-01)

RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin
by: Wendy Muñoz-Montaño, et al.
Published: (2021-08-01)

Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
by: Xue-Song Sun, et al.
Published: (2020-08-01)

Co-encapsulation of thymoquinone with docetaxel enhances the encapsulation efficiency into PEGylated liposomes and the chemosensitivity of MCF7 breast cancer cells to docetaxel
by: Fadwa Odeh, et al.
Published: (2019-11-01)

UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells
by: Yan Wu, et al.
Published: (2019-01-01)

Inhibition of Kpnβ1 mediated nuclear import enhances cisplatin chemosensitivity in cervical cancer
by: Ru-pin Alicia Chi, et al.
Published: (2021-02-01)

Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
by: Byrski T, et al.
Published: (2012-04-01)

Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
by: Byrski T, et al.
Published: (2012-01-01)

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
by: Byrski T, et al.
Published: (2011-06-01)

Os genes ERCC1 e RRM1 no carcinoma broncopulmonar ERCC1 and RRM1 genes in lung cancer
by: Lina Carvalho, et al.
Published: (2009-08-01)

Association between Polymorphisms of ERCC1 and Response in Patients with Advanced Non-small Cell Lung Cancer Receiving Cisplatin-based Chemotherapy
by: Yanfei GU, et al.
Published: (2010-04-01)

Correction of ERCC1 deficiency in mice
by: Selfridge, Jim
Published: (1999)

<i>BRCA1</i> Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer
by: William Jacot, et al.
Published: (2020-03-01)

Effects of Expression of ERCC1, RRM1 on Survival Trend of Lung Cancer with Cisplatin Combine Gemcitabine Chemotherapy after Surgical Resection
by: Min SONG, et al.
Published: (2009-05-01)

Impact of ERCC1 gene polymorphisms on response to cisplatin based therapy in oral squamous cell carcinoma (OSCC) patients
by: M L Avinash Tejasvi, et al.
Published: (2020-01-01)

Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression
by: Kaina Bernd, et al.
Published: (2010-09-01)

Corrigendum to “UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells”
by: Yan Wu, et al.
Published: (2020-01-01)

Correction to: Chemosensitizing and nephroprotective effect of resveratrol in cisplatin-treated animals
by: Abdel-Moneim M. Osman, et al.
Published: (2019-02-01)

Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
by: Ioannis Boukovinas, et al.
Published: (2008-01-01)

mRNA NFATC1 Expression in Genu Osteoarthritis with Effusion
by: Muhammad Reagan, et al.
Published: (2020-07-01)

ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer.
by: Michel B Choueiri, et al.
Published: (2015-01-01)

Docetaxel/cisplatin therapy in myasthenia gravis with hypertension/diabetes
by: Qi Guoyan, et al.
Published: (2017-12-01)

Inhibition of MGMT-mediated autophagy suppression decreases cisplatin chemosensitivity in gastric cancer
by: Yuanyuan Lei, et al.
Published: (2020-05-01)

Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel
by: Zhan Yang, et al.
Published: (2017-12-01)